Dr. Leahy received her Ph.D. in neuropharmacology from University College Dublin, Ireland, and her MBA from Columbia University.
She is CEO of PsychoGenics Inc. and also holds an adjunct associate professor of neuroscience position at Mount Sinai School of Medicine. Dr. Leahy has more than 30 years of experience in drug discovery, clinical development, and business development for pharmaceutical and biotechnology companies, including extensive knowledge of technology assessment, licensing, mergers and acquisitions, and strategic planning.
Dr. Leahy served on the Emerging Companies Section Governing Board for the board of directors of the Biotechnology Industry Organization (BIO), the board of directors of New York Bio, the Business Review Board for the Alzheimer’s Drug Discovery Foundation, and the Scientific Advisory Board of the International Rett Syndrome Foundation. She currently serves on the board of directors of PsychoGenics Inc., the board of directors of Intensity Therapeutics, a clinical-stage oncology company; the board of directors of Pasithea Therapeutics, a public company focused on the development of treatments for brain disorders; and is the chair of BioNJ, the trade association for New Jersey’s life science industry.